Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.76 |
| ▸ | ADORA1 | P30542 | 19/20 | 0.76 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.63 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2320379 | 0.87 | ADORA2A (1.00) | ADORA2AADORA1ADORA2B | |
| SCHEMBL2320502 | 0.87 | ADORA2A (0.71) | ADORA2AADORA1ADORA2B | |
| SCHEMBL2319807 | 0.86 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BCSNK1A1CLK4 | |
| SCHEMBL2319792 | 0.84 | ADORA2A (0.67) | ADORA2AADORA1ADORA2B | |
| SCHEMBL28799845 | 0.84 | ADORA2A (0.67) | ADORA2AADORA1ADORA2B | |
| SCHEMBL2322771 | 0.83 | ADORA1 (0.79) | ADORA2AADORA1ADORA2BCSNK1A1CLK4 | |
| SCHEMBL2327936 | 0.83 | ADORA2A (0.66) | ADORA2AADORA1ADORA2B | |
| SCHEMBL2324215 | 0.83 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BCSNK1A1CLK4 | |
| SCHEMBL30186658 | 0.83 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BCSNK1A1CLK4 | |
| SCHEMBL2322670 | 0.83 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BCSNK1A1CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160175314-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-06-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160175314-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885ADORA2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.